CMS “Retail” Insurance Model: How Prescription Drugs Fit In
This article was originally published in RPM Report
The ACA exchange rules regarding formularies aren’t written the way most in the biopharma industry would like. But that is likely to change over time, assuming CMS’ vision of a “retail” health insurance market is correct.
You may also be interested in...
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.